Get the Stockscreener App
28.82
6.78%
1.83
Hims Hers Health Inc stock is traded at $28.82, with a volume of 58.72M.
It is up +6.78% in the last 24 hours and up +15.37% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$26.99
Open:
$27.67
24h Volume:
58.72M
Relative Volume:
1.68
Market Cap:
$6.57B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
55.20
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
+48.33%
1M Performance:
+15.37%
6M Performance:
-42.11%
1Y Performance:
+5.84%
1-Day Range:
$27.40
$29.78
1-Week Range:
$19.30
$29.78
52-Week Range:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
28.82 | 6.57B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers May Have Just Rewritten Its Entire Business Model! - Smartkarma
Healthcare Technology Q4 2025 Report: Sector Revenue Beat & Stock SurgeNews and Statistics - IndexBox
Hims & Hers expands personalized digital healthcare platform - MSN
Hims & Hers Health, Inc. (NYSE:HIMS) Sees Large Drop in Short Interest - MarketBeat
HIMS Receives Upgrade Amid Positive Regulatory Outlook - GuruFocus
7 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Surge - Yahoo Finance
SA analyst upgrades/downgrades: NVDA, VZ, MRVL, HIMS - Seeking Alpha
Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum - International Business Times Australia
+7.34% for Hims & Hers Health stock as FDA eyes peptide drug policy change - Traders Union
What's Going On With Hims & Hers Shares - Benzinga
Here’s How Cedar Grove Capital Management Benefitted from Its Short Position in Hims & Hers Health (HIMS) - Yahoo Finance
Hims & Hers stock rises 14% as FDA schedules peptide compounding review - Yahoo Finance
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Hims Hers Health Surprise Signals New Healthcare Momentum Shift Ahead - Kalkine Media
HIMS Stock's Rally May Have Plenty Of Room Left: FDA Opens Door To Testosterone Therapy - Stocktwits
HIMS Stock Closes Another Day In The Green — But Retail Sees More Upside - Stocktwits
Why Is HIMS Stock Surging More Than 11% After-Hours Today? - Stocktwits
Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s - AOL.com
HIMS Stock Rises 7% on Potential FDA Regulatory Changes - GuruFocus
Eli Lilly's Oral Drug Clears CV Test, Hims Surges 14% - Gotrade
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies - Yahoo Finance
These Stocks Are Today’s Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More - Barron's
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions - TechStock²
What's Going On With Hims & Hers Stock Thursday - GuruFocus
RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here? - Barchart
Best Healthcare Stocks To Watch NowApril 16th - MarketBeat
Hims & Hers shares jump as FDA begins review of restricted peptide compounds - Yahoo! Finance Canada
HIMS: Positive Regulatory Developments Boost Stock Outlook - GuruFocus
Leerink reiterates Hims and Hers stock rating on peptide outlook - Investing.com
Hims & Hers Stock: How RFK Jr Loosened Peptide Regulations and Sent Shares Higher - Barron's
HIMS Stock Surges as FDA Plans Review on Peptide Compounding - GuruFocus
Hims rises as FDA considers broader peptides access; analysts see long-term win - Reuters
Hims & Hers (HIMS) Stock; Climbs 8% as FDA Peptide Review Sparks Expansion Hopes - CoinCentral
BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming? - AOL.com
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell? - The Globe and Mail
Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides - Yahoo Finance
Hims stock gains as FDA reviews peptides, Voyager secures NASA contract - Yahoo Finance
Hims & Hers extends gains on optimism over FDA peptide - Yahoo Finance
Biggest stock movers Thursday: AEHR, ABT, HOOD, COIN, and more (NYSE:HIMS) - Seeking Alpha
Market movers: Hims & Hers, Abbott Laboratories, QVC… - Proactive financial news
HIMS Stock Surges on FDA's Potential Regulatory Changes - GuruFocus
Hims & Hers Weight Loss Review (2026): What You Need To Know - Forbes
Hims & Hers stock rises as FDA schedules peptide review - Yahoo Finance
HIMS Maintained by B of A Securities -- Price Target Raised to $25 - GuruFocus
Bank of America Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price - MarketBeat
FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade) - Seeking Alpha
Hims & Hers (HIMS) Stock Jumps 13% as FDA Opens Door to Peptide Review - CoinCentral
HIMS Shares Surge 11% on FDA Regulatory News - GuruFocus
Hims & Hers (HIMS) Shares Surge on FDA Peptide Regulation Update - GuruFocus
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
6.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):